This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE)

Tipranks - Tipranks - Fri Jun 12, 6:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT), HeartFlow, Inc. (HTFL) and Neurogene (NGNE) with bullish sentiments.

Introducing TipRanks MCP for Agents

Abbott Laboratories (ABT)

Bank of America Securities analyst Travis Steed maintained a Buy rating on Abbott Laboratories today and set a price target of $120.00. The company’s shares closed last Wednesday at $89.17.

According to TipRanks.com, Steed is a 3-star analyst with an average return of 0.9% and a 48.7% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Bausch + Lomb Corporation, and Inspire Medical Systems. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abbott Laboratories with a $120.06 average price target, representing a 31.5% upside. In a report issued on May 29, Piper Sandler also maintained a Buy rating on the stock with a $115.00 price target.

See today’s best-performing stocks on TipRanks >>

HeartFlow, Inc. (HTFL)

Piper Sandler analyst Matthew O’Brien reiterated a Buy rating on HeartFlow, Inc. today and set a price target of $38.00. The company’s shares closed last Wednesday at $29.43.

According to TipRanks.com, O’Brien is ranked 0 out of 5 stars with an average return of -8.3% and a 35.5% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Shoulder Innovations, Inc., and Orchestra BioMed Holdings. ;'>

HeartFlow, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $37.00.

Neurogene (NGNE)

Neurogene received a Buy rating and a $69.00 price target from Guggenheim analyst Debjit Chattopadhyay on June 9. The company’s shares closed last Wednesday at $28.01.

According to TipRanks.com, Chattopadhyay is a 5-star analyst with an average return of 16.0% and a 46.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Ultragenyx Pharmaceutical, and Centessa Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurogene with a $80.00 average price target, representing a 176.8% upside. In a report issued on June 3, Rodman & Renshaw also initiated coverage with a Buy rating on the stock with a $70.00 price target.

Read More on ABT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).